The Latest Cardiac and Vascular News
DENVER–(BUSINESS WIRE)–Transverse Medical, Inc., developer of the POINT-GUARD™ Cerebral Embolic Protection medical device, is pleased to announce the appointment of Ian T. Meredith, MD to the Board of Directors. Professor Meredith brings over 35 years of experience and global leadership in cardiology coupled with successful clinical trials and device commercialization […]
NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson1 (NYSE: JNJ) announced today it has successfully completed the acquisition of V-Wave Ltd., a privately-held company focused on developing innovative treatment options for patients with heart failure. V-Wave will operate as part of Johnson & Johnson MedTech. The acquisition of V-Wave extends Johnson & Johnson […]
TORONTO, Oct. 11, 2024 (GLOBE NEWSWIRE) — Conavi Medical Corp. (formerly, “Titan Medical Inc.”) (“the “Resulting Issuer” or the “Corporation”) (TSX: TMD; OTC: TMDIF) is pleased to announce the completion of the previously announced business combination between Conavi Medical Inc. (“Conavi”) and the Corporation in an all-stock transaction, which constituted a reverse takeover of the Corporation (the “Transaction”). The combined company (the Resulting Issuer) will focus on continuing to commercialize and develop Conavi’s Novasight Hybrid™ System designed to guide common minimally invasive coronary procedures.
HENRICO, Va. and RALEIGH, N.C., Oct. 8, 2024 /PRNewswire/ — Compass Surgical Partners, Bon Secours Mercy Health and AlignedCardio today announced their plans to open Short Pump Cardiovascular Ambulatory Surgery Center in the Short Pump area of Henrico, Virginia. Scheduled to open in late…
HOUSTON, Oct. 8, 2024 /PRNewswire/ — Octagos Health, the leader in AI-powered remote cardiac monitoring, today announced significant advancements in product integration, enhanced AI functionality, and strategic talent investments. Following its recent $43 million Series B funding, the…
BERKELEY HEIGHTS, N.J., Oct. 08, 2024 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a new commercial supply contract with a top-five mid-sized dialysis operator for the supply of DefenCath® (taurolidine and heparin) to dialysis clinics in the US. This new agreement will provide access to DefenCath for adult patients with kidney failure receiving hemodialysis through a central venous catheter at more than 200 outpatient dialysis clinics located across the United States.
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
Amwell today announced Hello Heart is a partner in the Amwell clinical programs portfolio available on the Amwell Converge™ platform.
IRVINE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its third quarter 2024 financial results on Monday, October 28, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
October 07, 2024 08:00 AM Eastern Daylight Time REDWOOD CITY, Calif.–(BUSINESS WIRE)–InterVene, Inc., a clinical-stage medical device company dedicated to developing interventional solutions for chronic venous insufficiency (CVI), announced today the closing of its $13M Series A financing round. The financing was co-led by new investor Treo Ventures and existing […]
